Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19
Status:
Not yet recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
COVID 19 which started from a zoonotic transmission related to crowded markets was confirmed
to have a high potential for transmission to close contacts on 20 January 2020 by the
National Health Commission of China and it was announced as a pandemic by the WHO on 11 March
2020.
There is currently no clinically proven specific antiviral agent available for SARS-CoV-2
infection. Supportive treatment, including oxygen therapy, conservation fluid management, and
broad-spectrum antibiotics to cover secondary bacterial infection, remains the most important
management strategy.
Interestingly, sofosbuvir has recently been proposed as an antiviral for the SARS-CoV-2 based
on the similarity between the replication mechanisms of the HCV and the coronaviruses.
Aim of the study is to assess the safety and efficacy of of the addition of HCV treatment to
the standard regimen for the treatment of patients who are candidates to receive Hydroxy
Chloroquine according to Egyptian MOHP protocol